Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Authors
Gleeson, MCounsell, N
Cunningham, D
Chadwick, N
Lawrie, A
Hawkes, E
McMillan, A
Ardeshna, K
Jack, A
Smith, P
Mouncey, P
Pocock, C
Radford, John A
Davies, J
Turner, D
Kruger, A
Johnson, P
Gambell, J
Linch, D
Affiliation
Department of Medicine, The Royal Marsden Hospital, London and Surrey, UKIssue Date
2017-10-01
Metadata
Show full item recordAbstract
Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) 14 versus 21 randomised trial.Citation
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. 2017, 28 (10):2511-2516 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx353PubMed ID
28961838Type
ArticleLanguage
enDescription
Lymphoma Research TeamISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx353
Scopus Count
Collections
Related articles
- New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
- Authors: Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao HL, Liu Q, Jiang WQ, Huang HQ, Lin TY, Xia ZJ
- Issue date: 2016 Sep 13
- Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
- Authors: Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR
- Issue date: 2019 Oct
- Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
- Authors: Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R
- Issue date: 2012 Oct
- Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
- Authors: Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y
- Issue date: 2015 Mar
- Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
- Authors: Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D
- Issue date: 2017 Jul 1